Cellectis to Present Allogeneic CAR-T Data at EHA Congress in June 2026
Cellectis announced on Tuesday the presentation of clinical data on two allogeneic CAR-T candidates at the annual congress of the European Hematology Association (EHA), to be held from June 11 to 14, 2026 in Stockholm. The biotech will notably unveil Phase 1 results from the BALLI-01 trial evaluating lasmé-cel in relapsed or refractory acute lymphoblastic leukemia.
Lasmé-cel: A Complete Phase 1 Data Oral Presentation
The abstract presenting the complete Phase 1 data from the BALLI-01 trial has been selected for an oral presentation. Lasmé-cel is an allogeneic CAR-T targeting the CD22 antigen, evaluated in heavily pretreated patients with relapsed or refractory B-cell acute lymphoblastic leukemia (LLA-B).
These data will be presented by Nitin Jain, M.D., Professor of Medicine in the Leukemia Department at MD Anderson Cancer Center in Houston. According to the press release, the results highlight a safety profile and response rates in patients relapsing after multiple previous targeted therapies, including autologous CAR-T targeting the CD19 antigen.
Adrian Kilcoyne, M.D., Medical Director at Cellectis, stated: 'We are thrilled to present these important data at EHA. Most patients in the BALLI-01 study had exhausted all therapeutic options and faced a very grim prognosis. The depth of responses observed offers hope to these patients and demonstrates the potential of lasmé-cel to become an effective therapeutic option for those with unmet medical needs.'
The BALLI-01 study is currently recruiting patients for a pivotal Phase 2 trial. Interim data are expected to be unveiled in the fourth quarter of 2026. The oral presentation will take place on Saturday, June 13, from 5:15 PM to 6:30 PM (Paris time) in the session 'Advances in the Treatment of Lymphoblastic Leukemia'.
Éti-cel: Preliminary Mechanistic Results in Non-Hodgkin Lymphoma
The abstract from the Phase 1 NATHALI-01 study, evaluating éti-cel in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), has been accepted for a poster presentation. Éti-cel is a first-in-class dual CAR-T-cell product targeting CD20/CD22.
This preliminary analysis explores the relationship between exposure to alemtuzumab, the cellular expansion of éti-cel, cytokine dynamics, and clinical outcomes, providing initial mechanistic insights for optimizing the lymphodepletion regimen. The poster presentation will take place on Saturday, June 13, from 6:45 PM to 7:45 PM (Paris time) and will be presented by Emmanuel Bachy, M.D., Ph.D., Hematology, Lyon-Sud Hospital Center.
Phase 1 clinical data from the NATHALI-01 trial are expected to be unveiled in the fourth quarter of 2026.
